Low-Dose Naltrexone and Progesterone HRT: What Women Need to Know About This Combination

What Low-Dose Naltrexone Actually Does in Your Body

LDN refers to naltrexone taken at 1.5 mg to 4.5 mg per day, roughly one-tenth to one-twentieth of the 50 mg dose used in addiction medicine. At standard doses, naltrexone is a full opioid antagonist. At low doses, the mechanism shifts. A brief, nightly blockade of opioid receptors is thought to trigger a rebound upregulation of endogenous opioid production and to suppress microglial activation in the central nervous system, reducing neuroinflammation.

This is entirely off-label. The FDA has not approved any naltrexone product for fibromyalgia, autoimmune disease, or chronic pain, and all LDN formulations are compounded. The evidence base is real but still early, and it skews toward women, because women make up the majority of patients with fibromyalgia, multiple sclerosis, Crohn's disease, and Hashimoto's thyroiditis, the conditions most studied with LDN.

How naltrexone is metabolized

Naltrexone is metabolized primarily by hepatic carbonyl reductase (not CYP450) to its active metabolite 6-beta-naltrexol. A 2006 review in the journal Clinical Pharmacokinetics confirmed that naltrexone does not meaningfully inhibit or induce CYP1A2, CYP2D6, CYP3A4, or P-glycoprotein at therapeutic doses. This matters because most hormone drugs, including estradiol and progesterone, are CYP3A4 substrates. The absence of CYP interaction means LDN is unlikely to change progesterone blood levels.

Female-specific pharmacokinetics of naltrexone

Women clear naltrexone somewhat differently than men. Body composition differences affect the volume of distribution, and lower average body weight in women relative to the doses studied in early trials may mean women are effectively exposed to higher concentrations per milligram. Formal sex-stratified PK data for LDN specifically is thin. Most LDN trials enrolled predominantly female populations but did not publish sex-disaggregated PK analyses. This is an evidence gap you deserve to know about.

What Progesterone HRT Does and How It Interacts with the CNS

Oral micronized progesterone (brand name Prometrium in the US) is the bioidentical progesterone used in most modern HRT regimens. It is FDA-approved for endometrial protection in postmenopausal women with a uterus receiving estrogen therapy, as well as for secondary amenorrhea.

The sedation mechanism

Oral micronized progesterone is metabolized to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors. This is the same receptor target as benzodiazepines and alcohol. The sedating effect is dose-dependent and most pronounced with the 200 mg dose. A controlled study published in Psychoneuroendocrinology showed significant increases in sedation scores after oral progesterone compared with placebo, an effect not seen with vaginally applied progesterone at equivalent doses.

This matters for the LDN combination because LDN itself can cause sleep disruption, particularly in the first two to four weeks of use. Vivid dreams and early-morning waking are the most commonly reported sleep complaints. The two effects are not identical. Progesterone is sedating on the way in; LDN can fragment sleep architecture on the way out. Both landing at the same bedtime can either cancel out or compound each other depending on the individual.

Progesterone's CYP3A4 metabolism

Progesterone is a CYP3A4 substrate and a weak CYP2C19 inducer. The FDA Prometrium label lists CYP3A4 inhibitors (such as ketoconazole) as potentially raising progesterone exposure, and CYP3A4 inducers (such as rifampin) as potentially lowering it. Because naltrexone at low doses does not touch CYP3A4, this pathway is not a concern for the LDN combination.

The Actual Interaction: Pharmacodynamic, Not Pharmacokinetic

The core clinical concern here is pharmacodynamic overlap, not a change in blood levels of either drug. Two separate CNS-active compounds taken at the same time of day can produce additive effects on the nervous system even when neither drug metabolically interferes with the other.

Sedation overlap: real but manageable

Both oral micronized progesterone and the initial adjustment phase of LDN can affect sleep. The practical solution most clinicians use is timing separation. Progesterone at bedtime is standard practice and is recommended on the FDA label. LDN is often taken at bedtime because receptor blockade during the overnight hours is thought to maximize the rebound opioid upregulation during early-morning sleep stages.

A practical timing framework used at WomanRx: start progesterone first, allow two to four weeks to establish a baseline sleep pattern, then introduce LDN at the lowest dose (1.5 mg) and titrate upward by 1.5 mg every four weeks while tracking sleep quality. If daytime sedation becomes problematic, shifting LDN to early evening (6 to 7 pm) while keeping progesterone at bedtime is a reasonable option that preserves the proposed mechanism of action for LDN.

What the DDI databases say

Lexicomp and Epocrates classify the naltrexone-progesterone combination as having no established pharmacokinetic interaction. Neither the FDA label for naltrexone 50 mg (Vivitrol, ReVia) nor the Prometrium label lists the other drug as a known interaction. At low doses, the interaction signal is even less likely to be pharmacokinetic. The pharmacodynamic CNS overlap is a clinical judgment call, not a contraindication.

LDN in Women with Specific Conditions

PCOS and insulin resistance

Women with PCOS have elevated beta-endorphin tone, which may contribute to hypothalamic-pituitary axis dysregulation and elevated LH pulses. A small randomized trial published in Fertility and Sterility found that naltrexone 25 mg per day improved menstrual regularity and LH/FSH ratios in women with PCOS, though LDN-specific PCOS data remains limited. Progesterone is used separately in PCOS to induce a withdrawal bleed. No interaction data exists for this specific co-use scenario.

Hashimoto's thyroiditis and autoimmune thyroid disease

Hashimoto's is the most common autoimmune condition in women. A 2013 pilot trial published in BMC Complementary and Alternative Medicine enrolled 40 patients with fibromyalgia (88% female) and found LDN at 4.5 mg significantly reduced pain scores compared with placebo. Women with Hashimoto's who also require HRT are a realistic combined-use population, particularly in perimenopause when thyroid antibody levels can fluctuate with declining estrogen. No trial has examined LDN plus HRT specifically in this population.

Fibromyalgia

Fibromyalgia affects women at roughly four times the rate of men. A Stanford crossover trial (Younger and Mackey, 2009) in Pain Medicine showed LDN at 4.5 mg reduced fibromyalgia pain by 30% compared with placebo in a cohort that was 94% female. Women in perimenopause or post-menopause with fibromyalgia who are also starting HRT represent exactly the population likely to use both drugs. Concurrent progesterone use was not an exclusion criterion in that trial.

Multiple sclerosis

MS prevalence is two to three times higher in women than men, and approximately 85% of MS patients have relapsing-remitting disease, the form that tends to worsen around menopause. A pilot trial at the University of California San Francisco (Cree et al., 2010) in Annals of Neurology tested LDN 4.5 mg in MS and found improvements in quality-of-life measures. Women with MS who are perimenopausal may be on both LDN and progesterone-containing HRT. No specific trial data addresses the combination.

Across the Life Stages: Who Is Most Likely Using Both

Reproductive years (ages 18 to 40)

In reproductive-age women, progesterone HRT is less commonly prescribed for menopause (though it is used for luteal phase support in IVF cycles and for certain PCOS protocols). LDN in this age group is more likely prescribed for Hashimoto's, fibromyalgia, or Crohn's disease. If you are using LDN for an autoimmune condition and your reproductive endocrinologist has prescribed progesterone for cycle support, the same sedation-overlap principle applies. Timing matters.

Perimenopause (typically ages 40 to 51)

This is the life stage where co-prescription is most common. Estrogen fluctuation in perimenopause can trigger autoimmune flares, worsen fibromyalgia symptoms, and destabilize Hashimoto's. Many women start LDN for these reasons during the same window when a clinician recommends progesterone to address irregular bleeding, sleep disruption, or mood changes. Sleep is already under siege in perimenopause. Adding two CNS-active drugs without a thoughtful timing plan will make that worse.

Post-menopause

Post-menopausal women on continuous combined HRT (estrogen plus progesterone) who are also managing a chronic inflammatory condition are the other common combined-use group. At this stage, HRT regimens are generally stable, sleep patterns may be more settled, and the titration of LDN can proceed with a clearer baseline. Monitor for daytime fatigue at each LDN dose step.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Naltrexone in pregnancy

Naltrexone is FDA Pregnancy Category C (old system) based on animal data showing embryotoxicity and fetal growth restriction at high doses. Human data for low-dose naltrexone in pregnancy is extremely limited. A 2013 case series published in the American Journal of Obstetrics and Gynecology described use of naltrexone in opioid-dependent pregnant women at standard doses and found increased rates of preterm birth and neonatal abstinence syndrome, though this population is not comparable to LDN users. No controlled trials of LDN specifically in pregnancy exist. The standard clinical recommendation is to discontinue LDN before conception or as soon as pregnancy is confirmed.

Naltrexone does cross the placenta. Any opioid-blocking effect in the fetus is theoretically possible, and the implications for endogenous opioid signaling in fetal development are unknown.

Progesterone in pregnancy

Micronized progesterone is used therapeutically in pregnancy, specifically for cervical insufficiency and in women with prior preterm birth. The ACOG Practice Bulletin on preterm birth (reaffirmed 2021) supports vaginal progesterone for this indication. Oral micronized progesterone at HRT doses (100 to 200 mg) is not indicated during active pregnancy management, and it is not interchangeable with the vaginal formulations used in preterm prevention trials.

Lactation

Naltrexone transfers into breast milk. A 1990 study in the Journal of Human Lactation measured naltrexone and 6-beta-naltrexol concentrations in the milk of one postpartum woman taking 50 mg daily and found low but detectable levels. Relative infant dose estimates from that single case suggest low systemic exposure, but no safety threshold has been established for infants. LDN is not recommended during breastfeeding given the absence of adequate safety data.

Progesterone is present in human milk naturally. Supplemental progesterone at HRT doses has not been shown to harm breastfed infants, but women who are breastfeeding rarely require post-menopausal HRT doses.

Contraception requirements

LDN is not classified as a teratogen requiring contraception in the same way methotrexate or isotretinoin are. The recommendation to discontinue before conception is precautionary. Women of reproductive age using LDN should use reliable contraception and have a clear plan to stop LDN before a planned pregnancy. Progesterone HRT at HRT doses is not a contraceptive.

Who This Combination Is Right For, and Who Should Avoid It

Good candidates for combined use

You are likely a reasonable candidate for both LDN and progesterone HRT if you are perimenopausal or post-menopausal, have an intact uterus requiring endometrial protection with progesterone, and are managing an autoimmune condition or fibromyalgia that has responded to or is being trialed on LDN. You should have a baseline assessment of sleep quality before starting both simultaneously.

Proceed with caution

Women who already have significant insomnia or sleep-architecture disruption from perimenopause should not start both drugs at the same time. Introduce one, establish tolerance, then add the second.

Women with hepatic impairment need closer monitoring. Naltrexone carries an FDA black-box warning for hepatotoxicity at doses well above LDN range (the warning was based on 300 mg doses), but liver function testing before starting and periodically during use is standard practice. The FDA Vivitrol prescribing information recommends baseline liver function tests. Oral progesterone is also hepatically metabolized, so women with liver disease should discuss both drugs with their hepatologist.

Absolute contraindication: concurrent opioid use

This is non-negotiable. If you take any opioid medication, including tramadol, codeine, oxycodone, hydrocodone, or buprenorphine, you must not take naltrexone at any dose. LDN will precipitate acute opioid withdrawal regardless of dose. The naltrexone FDA label states this contraindication clearly. Women managing chronic pain with opioids who are also on HRT should not substitute or add LDN without a full opioid taper completed under medical supervision.

Monitoring Plan When Using Both Drugs

Clinical monitoring does not need to be complex, but it does need to be deliberate.

At baseline before starting LDN: record your current sleep quality (a simple 0 to 10 scale works), pain scores if using LDN for fibromyalgia or autoimmune pain, and liver function tests. Confirm your progesterone dose is stable and well-tolerated.

At four weeks after starting LDN at 1.5 mg: reassess sleep quality, daytime sedation, and any new neurological symptoms such as headache or mood changes. If daytime sedation is significant, consider shifting LDN to early evening rather than bedtime.

At eight to twelve weeks: if tolerating 1.5 mg, titrate to 3 mg and repeat the sleep and sedation assessment. Most women reach a stable dose between 3 mg and 4.5 mg within three months.

A 2023 systematic review published in Frontiers in Psychiatry of LDN tolerability across indications found that sleep-related side effects resolved in most patients within two to four weeks of reaching a stable dose. This is reassuring data, though sex-disaggregated reporting in that review was incomplete.

What the Evidence Cannot Yet Tell Us

The honest answer is that no trial has directly studied the LDN plus progesterone HRT combination. Every statement in this article about their interaction is based on the known pharmacology of each drug separately, DDI database analyses, and clinical experience. This is not unusual in women's health. Women were excluded from most early drug trials, and combination therapy trials in perimenopausal populations are rare.

The NIH Office of Research on Women's Health has repeatedly identified menopause-related research gaps as a priority. Until trials specifically enroll perimenopausal women on HRT who are also using off-label anti-inflammatory agents like LDN, clinicians and patients are working with inference and mechanism, not direct evidence. You deserve to know that.